Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study

Ipilimumab (IPI) blocks CTLA-4 immune checkpoint resulting in T cell activation and enhanced antitumor immunity. IPI improves overall survival (OS) in 22% of patients with metastatic melanoma (MM). We investigated the association of CTLA-4 single nucleotide variants (SNVs) with best overall response...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Immunol
Main Authors: Queirolo, Paola, Dozin, Beatrice, Morabito, Anna, Banelli, Barbara, Piccioli, Patrizia, Fava, Cristiana, Leo, Claudio, Carosio, Roberta, Laurent, Stefania, Fontana, Vincenzo, Ferrucci, Pier Francesco, Martinoli, Chiara, Cocorocchio, Emilia, Battaglia, Angelo, Ascierto, Paolo A., Capone, Mariaelena, Simeone, Ester, De Galitiis, Federica, Pagani, Elena, Antonini Cappellini, Gian Carlo, Marchetti, Paolo, Guida, Michele, Tommasi, Stefania, Mandalà, Mario, Merelli, Barbara, Quaglino, Pietro, Fava, Paolo, Guidoboni, Massimo, Romani, Massimo, Spagnolo, Francesco, Pistillo, Maria Pia
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2017
Assuntos:
Immunology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5388686/
https://ncbi.nlm.nih.gov/pubmed/28446908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.00386
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares